DMACNasdaqPharmaceutical PreparationsFiscal year ends December 31
DiaMedica Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$7.87+0.30 (+3.96%)
Close on Oct 19, 2026
- Market cap
- $424.15M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -73.1% | -67.7% | |
| Return on assets | – | -66.2% | -60.8% | |
| Current ratio | – | 13.77 | 11.81 | |
| Diluted shares | – | 16M | 47M |
Where the cash went
Fiscal 2021 to 2025, five years combined
DiaMedica Therapeutics generated $93.63M from operations and spent $192.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$93.63M
Used
$192.00K
Capital expenditure$192.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1146.8%
×Asset turnover0.05×
×Equity multiplier1.13×
=Return on equity, FY2018-64.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2018 | -1146.8% | 0.05× | 1.13× | -64.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$32.77M
- Cash generatingOperating cash flow above zero-$29.06M
- Return on assets improvedROA up on the prior year-45.1% → -70.7%
- Earnings backed by cashOperating cash flow above net income-$29.06M vs -$32.77M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose8.28 → 11.81
- No dilutionShare count did not rise40M → 47M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –